Alzheimer's disease treatment encompasses pharmacological and non-pharmacological approaches aimed at modifying disease progression, managing symptoms, and improving quality of life. Current treatments include disease-modifying therapies targeting amyloid and tau, symptomatic treatments for cognitive and behavioral symptoms, and lifestyle interventions.
Monoclonal antibodies that remove amyloid-beta plaques:
| Drug |
Target |
FDA Status |
Key Trial Results |
| Lecanemab |
Aβ protofibrils |
Approved 2023 |
27% slowing of decline |
| Donanemab |
N-terminal Aβ |
Approved 2024 |
35% slowing of decline |
| Aducanumab |
Aβ plaques |
Approved 2021 |
Controversial efficacy |
| Gantenerumab |
Aβ plaques |
Withdrawn |
Negative Phase 3 |
Drugs targeting tau pathology:
- LMTM (Methylene Blue derivative): Tau aggregation inhibitor
- Anti-tau antibodies: Various in clinical development
- Tau kinase inhibitors: Target phosphorylation pathways
- Synaptic plasticity enhancers: Ampakines
- Neuroprotective agents: Azeliragon
- Metabolic modulators: Type 2 diabetes drugs
¶ Behavioral and Psychological Symptoms
- Antidepressants: SSRIs for depression and anxiety
- Antipsychotics: Risperidone, olanzapine (cautious use)
- Prazosin: For agitation
- Brexpiprazole: For agitation in AD
- Cognitive training: Computerized brain training
- Reminiscence therapy: Using memories to improve mood
- Reality orientation: Time and place reinforcement
- Physical exercise: Regular aerobic activity
- Social engagement: Maintaining relationships
- Sleep hygiene: Managing sleep disturbances
- Diet: Mediterranean diet, MIND diet
- Education programs: Understanding disease progression
- Support groups: Emotional support
- Respite care: Caregiver relief
- Biogen pipelines: Multiple antibodies in trials
- Vaccines: ACI-35 and others
- Gene therapy: AAV-based treatments
- Cell therapy: Stem cell approaches
- A4 study: Anti-amyloid treatment in preclinical AD
- DIAN-TU: Genetic forms of AD
- Generation studies: APOE-targeted prevention
¶ TREM2 Agonists and Microglial Activation
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a cell surface receptor primarily expressed on microglia in the brain. It plays a critical role in modulating microglial function, including phagocytosis, metabolic reprogramming, survival signaling, and clustering around pathological protein deposits. Loss-of-function variants in TREM2 (such as R47H, R62H) significantly increase Alzheimer's disease risk, making TREM2 activation a promising therapeutic strategy.
TREM2 agonists work by:
- Enhancing phagocytosis: Activating microglia to clear amyloid-beta plaques and cellular debris more efficiently
- Supporting disease-associated microglia (DAM): Promoting the inflammatory metabolic state of protective microglial phenotypes
- Providing survival signals: Preventing microglial apoptosis and maintaining cell viability
- Promoting plaque clustering: Facilitating microglial clustering around amyloid plaques to form protective barriers
AL002 is a monoclonal antibody designed to activate TREM2 by binding to a distinct epitope that promotes receptor clustering and signaling. It represents the first TREM2-targeting antibody to enter clinical trials for Alzheimer's disease.
- Phase 1 (completed): Demonstrated dose-dependent engagement of TREM2 and acceptable safety profile in healthy volunteers and AD patients
- Phase 2 (INVOKE-2, ongoing): Evaluating clinical efficacy in patients with early Alzheimer's disease
- Enrollment: Approximately 265 participants with early AD
- Primary endpoints: Change in amyloid PET, cognitive measures (ADAS-Cog13, ADCS-ADL), and multiple fluid and imaging biomarkers
- Mechanism: Intended to optimize TREM2 signaling to improve microglia activity and counteract decreased TREM2 functionality
AL003 uses a different mechanism, potentially acting as a TREM2-activating antibody with enhanced brain penetration.
- Status: Phase 1 completed, clinical development continued with strategic partner
| Agent |
Company |
Mechanism |
Stage |
Notes |
| AL002 |
Alector/AbbVie |
TREM2 agonist mAb |
Phase 2 |
INVOKE-2 trial in early AD |
| AL003 |
Alector |
TREM2 agonist mAb |
Phase 1 |
Brain-penetrant |
| DNL311 |
Denali/Adimab |
TREM2-targeting antibody |
Preclinical |
Enhanced brain penetration |
Patients being considered for TREM2 agonist trials typically meet the following criteria:
- Age: Typically 50-85 years
- Diagnosis: Mild cognitive impairment (MCI) due to AD or mild Alzheimer's disease
- Amyloid status: Confirmed amyloid-positive via PET scan or CSF biomarkers
- MMSE score: Usually 20-26 (mild disease)
- Exclusion: No significant vascular disease, psychiatric conditions, or other neurodegenerative diseases
¶ Safety and Adverse Effects
Similar to other antibody therapies targeting immune pathways:
- ARIA-E: Amyloid-related imaging abnormalities - edema; monitoring required via MRI
- ARIA-H: Microhemorrhages; particular attention in anti-amyloid combination trials
- Infusion reactions: Potential for cytokine release with first doses
- Infections: Monitor for respiratory and urinary tract infections
- Long-term immune modulation: Effects on microglial function require extended monitoring
- CSF sTREM2: Soluble TREM2 in cerebrospinal fluid reflects microglial activation and may predict treatment response
- Genetic stratification: Patients with TREM2 risk variants (R47H, R62H) may particularly benefit from TREM2 agonism
- Amyloid status: Required for patient selection as amyloid plaques are the primary ligand for microglial phagocytosis
- Early diagnosis: Critical for treatment benefit
- Comprehensive assessment: Cognitive, functional, behavioral
- Individualized care: Tailored to patient needs
- Regular monitoring: Track progression and treatment response